Ralliant Corporation (NYSE:RAL) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Ralliant Corporation (NYSE:RAL) have received a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $73.00.

A number of brokerages have recently weighed in on RAL. Evercore started coverage on Ralliant in a report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 target price on the stock. Wall Street Zen upgraded shares of Ralliant from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Royal Bank Of Canada boosted their price objective on shares of Ralliant from $64.00 to $71.00 and gave the company a “sector perform” rating in a research report on Thursday, July 16th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Finally, Oppenheimer increased their target price on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th.

Ralliant Stock Performance

Shares of RAL stock opened at $69.55 on Friday. The company has a market capitalization of $7.78 billion and a price-to-earnings ratio of -6.36. Ralliant has a 1-year low of $37.27 and a 1-year high of $75.41. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. The stock’s fifty day simple moving average is $66.43 and its 200-day simple moving average is $53.80.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million during the quarter. Ralliant’s quarterly revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, sell-side analysts predict that Ralliant will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is currently -1.83%.

Institutional Trading of Ralliant

A number of institutional investors have recently bought and sold shares of RAL. Phocas Financial Corp. raised its stake in shares of Ralliant by 81.2% during the 4th quarter. Phocas Financial Corp. now owns 157,116 shares of the company’s stock worth $7,999,000 after purchasing an additional 70,403 shares in the last quarter. Teacher Retirement System of Texas grew its stake in shares of Ralliant by 6.9% in the 4th quarter. Teacher Retirement System of Texas now owns 570,878 shares of the company’s stock valued at $29,063,000 after buying an additional 36,800 shares in the last quarter. Alpha Omega Wealth Management LLC grew its stake in shares of Ralliant by 615.8% in the 4th quarter. Alpha Omega Wealth Management LLC now owns 40,291 shares of the company’s stock valued at $2,051,000 after buying an additional 34,662 shares in the last quarter. Walleye Capital LLC acquired a new position in Ralliant in the first quarter worth approximately $4,525,000. Finally, M&T Bank Corp increased its holdings in Ralliant by 464.6% in the fourth quarter. M&T Bank Corp now owns 42,359 shares of the company’s stock worth $2,156,000 after buying an additional 34,857 shares during the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.